OxStem appoint new Chief Scientific Officer

OxStem has appointed Georg Terstappen as new CSO at the regenerative drug discovery unit. Mr Terstappen has been in the industry for 25 years and has worked with Abbott, Abbvie, Bayer, and as co-founder and CEO of drug discovery start-up Sienna Biotech. His most recent post was at GSK as Head of Platform Technologies & Science China, responsible for clinical development.
Professor of Medicinal Chemistry at the University of Oxford, and Scientific Co-founder and Director of Stemistry of OxStem, Angela Russell, said: “Georg’s experience in discovery biology and translational research, is highly complementary to the strong medicinal chemistry and deep disease area expertise of the OxStem scientific team. We look forward to a close collaboration with Georg to realise OxStem’s programme objectives.”
Chairman and CEO at OxStem, Michael Stein, said: “I warmly welcome Georg to OxStem and we are thrilled to have attracted such an accomplished drug hunter to the OxStem Team. Georg brings extensive R&D management experience to OxStem and his track record of delivery in both pharma and biotech is well-evidenced. He joins OxStem at a time of significant growth and acceleration in our discovery programmes and we look forward to working with him on our important mission to deliver innovative medicines based on the translation of our breakthrough science.”